New gene editing tool shows promise for treating diseases with multiple mutations

"CRISPR has revolutionized how we think about gene editing, but it has limitations. CRISPR can't target every location in the genome, and it can't fix the thousands of mutations present in diseases like cystic fibrosis," said co-senior author Omar Abudayyeh, PhD, an investigator at the Gene and Cell Therapy Institute (GCTI) at Mass General Brigham and Engineering in Medicine Division in the Department of Medicine at Brigham and Women's Hospital (BWH). "When we started our lab, one of the big things we wanted to figure out was how to insert large pieces of genes, or even entire genes, to replace faulty ones. This would allow us to target every mutation for a disease with a single gene editing construct."

STITCHR harnesses the power of enzymes from genetic elements called retrotransposons, which are found in all eukaryotic cells, including animals, fungi, and plants. They are often called "jumping genes" for their tendency to move around and insert themselves into the genome. The researchers recognized how the copy-and-paste mechanism they use to move could be repurposed to edit genes at specific locations.

The research team, with lead study author Christopher Fell, PhD, also of the GCTI and BWH Division of Engineering in Medicine, then used a computational approach to screen thousands of retrotransposons to identify some that could potentially be reprogrammed, which they tested in the lab. They narrowed down to a final candidate, which was combined with the nickase enzyme from the CRISPR gene editing system to help seamlessly insert the genes, to form the final STITCHR system.

The researchers plan to continue enhancing efficiency of the system and are working towards translating STITCHR for clinical applications.

"By studying basic biology in our cells, we can find inspiration for new tools. These can expand our cell engineering capabilities and lead to creation of new medicines and therapies for both rare and common diseases," said co-corresponding author Jonathan Gootenberg, PhD, of the Center for Virology and Vaccine Research at BIDMC, member of the Gene and Cell Therapy Institute at Mass General Brigham, and member of the faculty at Harvard Medical School.